This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Walker, S E Articles by McMurray, R W Search for Related Content PubMed PubMed Citation Articles by Walker, S E Articles by McMurray, R W Social Bookmarking                         What's this?

Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine

Specialty Care Service Line, Harry S Truman Memorial Veterans Hospital, Columbia, MO, USA; Department of Internal Medicine, University of Missouri, Columbia, MO, USA; Harry S Truman Memorial Veterans Hospital, Research, 800 Hospital Drive, Columbia, MO 65201, USA sewk{at}tranquility.net

K L Smarr

Mental Health Service Line, Harry S Truman Memorial Veterans Hospital, Columbia, MO, USA; Research Service, Harry S Truman Memorial Veterans Hospital, Columbia, MO, USA

J C Parker

Mental Health Service Line, Harry S Truman Memorial Veterans Hospital, Columbia, MO, USA

D N Weidensaul

Department of Internal Medicine, University of Missouri, Columbia, MO, USA

W Nelson

Research Service, Harry S Truman Memorial Veterans Hospital, Columbia, MO, USA

R W McMurray

Department of Internal Medicine, University of Missouri, Columbia, MO, USA

We tested mood states in patients with systemic lupus erythematosus (SLE) treated with the prolactin-lowering drug, bromocriptine. Bromocriptine was given to seven patients in an open-label study to test its effects on active SLE. Two independent measures of SLE activity, the SLE Activity Measure (SLAM) and the SLE Disease Activity Index (SLEDAI), were scored and the Symptom Questionnaire (SQ) mood survey was administered at entry and at 6 monthly follow-up visits. The SLAM and SLEDAI scores improved significantly during treatment. Two of the four mood scales in the SQ (Anxiety Scale and Anger – Hostility Scale) showed significant improvement compared to the entry value at least once during treatment. Significant improvement was also observed in the Total Distress Score, which is the sum of the four scales and is a more sensitive measure of distress than the score of an individual scale. Depression, anxiety, somatic complaints, and total distress correlated positively with SLAM and/or SLEDAI scores. The Anxiety Scale and the Total Distress Score improved with treatment and did correlate positively with SLE activity. In contrast, the Anger – Hostility Scale improved with treatment but did not correlate with SLE activity.

Key Words: bromocriptine • prolactin • mood • lupus • autoimmunity • therapy

Lupus, Vol. 9, No. 7, 527-533 (2000)
DOI: 10.1177/096120330000900709


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L J Jara, O Vera-Lastra, J M Miranda, M Alcala, and J Alvarez-Nemegyci Prolactin in human systemic lupus erythematosus Lupus, October 1, 2001; 10(10): 748 - 756. [Abstract] [PDF]

				S E Walker Bromocriptine treatment of systemic lupus erythematosus Lupus, October 1, 2001; 10(10): 762 - 768. [Abstract] [PDF]

				S E Walker Treatment of systemic lupus erythematosus with bromocriptine Lupus, March 1, 2001; 10(3): 197 - 202. [Abstract] [PDF]